Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13084
UPID:
RM28_HUMAN
Alternative names:
39S ribosomal protein L28, mitochondrial; Melanoma antigen p15; Melanoma-associated antigen recognized by T-lymphocytes
Alternative UPACC:
Q13084; B2RCM4; D3DU46; Q4TT39; Q96S26; Q9BQD8; Q9BR04
Background:
The Large ribosomal subunit protein bL28m, also known as 39S ribosomal protein L28, mitochondrial, Melanoma antigen p15, and Melanoma-associated antigen recognized by T-lymphocytes, plays a crucial role in the mitochondrial ribosome. Its primary function is to contribute to the synthesis of proteins within the mitochondria, a process essential for cellular energy production and metabolic functions.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL28m could open doors to potential therapeutic strategies. Its involvement in mitochondrial protein synthesis positions it as a key player in cellular metabolism and energy production, making it a potential target for addressing metabolic disorders and diseases related to mitochondrial dysfunction.